These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 2676261)

  • 21. Hyperlipidemia and coronary atherosclerosis: a review.
    Inkeles S; Eisenberg D
    Medicine (Baltimore); 1981 Mar; 60(2):110-23. PubMed ID: 7012540
    [No Abstract]   [Full Text] [Related]  

  • 22. [Determination of potentially atherogenic triglyceride-rich lipoprotein particles].
    Alaupovic P; Blankenhorn DH
    Klin Wochenschr; 1990; 68 Suppl 22():38-42. PubMed ID: 2087077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the pathogenesis of atherosclerosis.
    Wissler RW
    Am J Med; 1991 Jul; 91(1B):3S-9S. PubMed ID: 1867233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis of artherosclerosis; some advances from using animal models.
    Clarkson TB; Prichard RW; Bullock BC; St Clair RW; Lehner ND; Jones DC; Wagner WD; Rudel LL
    Exp Mol Pathol; 1976 Jun; 24(3):264-86. PubMed ID: 179846
    [No Abstract]   [Full Text] [Related]  

  • 25. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study.
    Kannel WB; Castelli WP; Gordon T
    Ann Intern Med; 1979 Jan; 90(1):85-91. PubMed ID: 217290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Arteriosclerosis in primary hyperlipoproteinemia].
    Kucerová L; Voslárová Z; Papezová R
    Sb Lek; 1973 Jun; 75(6):161-8. PubMed ID: 4709455
    [No Abstract]   [Full Text] [Related]  

  • 27. Lipoproteins and the pathogenesis of atherosclerosis.
    Steinberg D
    Circulation; 1987 Sep; 76(3):508-14. PubMed ID: 3621517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.
    Shoji T; Nishizawa Y; Kawagishi T; Tanaka M; Kawasaki K; Tabata T; Inoue T; Morii H
    Atherosclerosis; 1997 Jun; 131(2):229-36. PubMed ID: 9199276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmune hyperlipidemia in a patient. Atherosclerotic course and chaning immunoglobulin pattern during 21 years of study.
    Lewis LA; deWolfe VD; Butkus A; Page IH
    Am J Med; 1975 Aug; 59(2):208-18. PubMed ID: 168771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study.
    Castelli WP; Anderson K
    Am J Med; 1986 Feb; 80(2A):23-32. PubMed ID: 3946458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical significance of remnant-lipoprotein].
    Nakamura Y; Miida T
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():22-5. PubMed ID: 15658253
    [No Abstract]   [Full Text] [Related]  

  • 32. [Children and dyslipemia].
    Assmann G; Davignon J; Fernández-Cruz A; Gotto AM; Jacotot B; Lewis B; Paoletti R
    Rev Clin Esp; 1990 Mar; 186(4):178-86. PubMed ID: 2195607
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical relevance of hyperlipidemia.
    Mancini M; Pauciullo P
    Cardiovasc Drugs Ther; 1990 Oct; 4(5):1385-8. PubMed ID: 2278873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Casein and soy protein isolate in experimental atherosclerosis: influence on hyperlipidemia and lipoprotein oxidation.
    Damasceno NR; Gidlund MA; Goto H; Dias CT; Okawabata FS; Abdalla DS
    Ann Nutr Metab; 2001; 45(1):38-46. PubMed ID: 11244186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remnant lipoproteins as strong key particles to atherogenesis.
    Fujioka Y; Ishikawa Y
    J Atheroscler Thromb; 2009 Jun; 16(3):145-54. PubMed ID: 19556722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The basis for a preventive cardiovascular program.
    Krehl WA
    J Occup Med; 1973 Jan; 15(1):45-7. PubMed ID: 4684727
    [No Abstract]   [Full Text] [Related]  

  • 38. Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias.
    CMAJ; 1990 Jun; 142(12):1371-82. PubMed ID: 2190685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesterol, lipoproteins, and coronary heart disease in women.
    Bush TL; Fried LP; Barrett-Connor E
    Clin Chem; 1988; 34(8B):B60-70. PubMed ID: 3042201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness.
    Hodis HN; Mack WJ; Dunn M; Liu C; Liu C; Selzer RH; Krauss RM
    Circulation; 1997 Apr; 95(8):2022-6. PubMed ID: 9133510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.